Safety and efficacy of human growth hormone treatment in girls with Turner syndrome.
Identifieur interne : 004F72 ( PubMed/Checkpoint ); précédent : 004F71; suivant : 004F73Safety and efficacy of human growth hormone treatment in girls with Turner syndrome.
Auteurs : D A Price [Royaume-Uni] ; P E Clayton ; E H Crowne ; C R RobertsSource :
- Hormone research [ 0301-0163 ] ; 1993.
Descripteurs français
- KwdFr :
- Adolescent, Analyse de régression, Comportement (), Crises épileptiques (), Croissance (), Encoprésie (), Encoprésie (psychologie), Enfant, Femelle, Glycémie (analyse), Hormone de croissance (effets indésirables), Hormone de croissance (usage thérapeutique), Humains, Hémoglobine A glycosylée (analyse), Lymphoedème (), Pression sanguine (), Protéines recombinantes (effets indésirables), Protéines recombinantes (usage thérapeutique), Relation dose-effet des médicaments, Syndrome de Turner (psychologie), Syndrome de Turner (traitement médicamenteux), Taille (), Triglycéride (sang), Troubles des tics (), Énurésie (), Énurésie (psychologie).
- MESH :
- analyse : Glycémie, Hémoglobine A glycosylée.
- effets indésirables : Hormone de croissance, Protéines recombinantes.
- psychologie : Encoprésie, Syndrome de Turner, Énurésie.
- sang : Triglycéride.
- traitement médicamenteux : Syndrome de Turner.
- usage thérapeutique : Hormone de croissance, Protéines recombinantes.
- Adolescent, Analyse de régression, Comportement, Crises épileptiques, Croissance, Encoprésie, Enfant, Femelle, Humains, Lymphoedème, Pression sanguine, Relation dose-effet des médicaments, Taille, Troubles des tics, Énurésie.
English descriptors
- KwdEn :
- Adolescent, Behavior (drug effects), Blood Glucose (analysis), Blood Pressure (drug effects), Body Height (drug effects), Child, Dose-Response Relationship, Drug, Encopresis (chemically induced), Encopresis (psychology), Enuresis (chemically induced), Enuresis (psychology), Female, Growth (drug effects), Growth Hormone (adverse effects), Growth Hormone (therapeutic use), Hemoglobin A, Glycosylated (analysis), Humans, Lymphedema (chemically induced), Recombinant Proteins (adverse effects), Recombinant Proteins (therapeutic use), Regression Analysis, Seizures (chemically induced), Tic Disorders (chemically induced), Triglycerides (blood), Turner Syndrome (drug therapy), Turner Syndrome (psychology).
- MESH :
- chemical , adverse effects : Growth Hormone, Recombinant Proteins.
- chemical , analysis : Blood Glucose, Hemoglobin A, Glycosylated.
- chemical , blood : Triglycerides.
- chemically induced : Encopresis, Enuresis, Lymphedema, Seizures, Tic Disorders.
- drug effects : Behavior, Blood Pressure, Body Height, Growth.
- drug therapy : Turner Syndrome.
- psychology : Encopresis, Enuresis, Turner Syndrome.
- chemical , therapeutic use : Growth Hormone, Recombinant Proteins.
- Adolescent, Child, Dose-Response Relationship, Drug, Female, Humans, Regression Analysis.
Abstract
Six major adverse medical events (AMEs) and 44 minor AMEs were recorded in 6 and 23 patients, respectively, during human growth hormone (GH) treatment of Turner syndrome, equivalent to 118 treatment years. During the first year of GH treatment, there was no change in the SD score (SDS) for systolic or diastolic blood pressure. In a subgroup of 20 patients, there was no change in psychological tests, oral glucose tolerance, glycosylated haemoglobin or serum triglycerides over the first year of GH treatment. The mean total serum cholesterol level fell over this period. The low incidence of adverse medical problems during GH treatment complemented its efficacy. Height velocity in the first year was 7.7 +/- 1.8 cm/year (mean +/- SD) and was correlated with maternal height SDS, though not with paternal height SDS. Some 36% of first-year height velocity SDS could be predicted by the dose of GH and maternal height SDS.
PubMed: 8359788
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:8359788Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and efficacy of human growth hormone treatment in girls with Turner syndrome.</title><author><name sortKey="Price, D A" sort="Price, D A" uniqKey="Price D" first="D A" last="Price">D A Price</name><affiliation wicri:level="1"><nlm:affiliation>Department of Child Health, Manchester University, Royal Manchester Children's Hospital, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Child Health, Manchester University, Royal Manchester Children's Hospital</wicri:regionArea><wicri:noRegion>Royal Manchester Children's Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Clayton, P E" sort="Clayton, P E" uniqKey="Clayton P" first="P E" last="Clayton">P E Clayton</name></author><author><name sortKey="Crowne, E H" sort="Crowne, E H" uniqKey="Crowne E" first="E H" last="Crowne">E H Crowne</name></author><author><name sortKey="Roberts, C R" sort="Roberts, C R" uniqKey="Roberts C" first="C R" last="Roberts">C R Roberts</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:8359788</idno><idno type="pmid">8359788</idno><idno type="wicri:Area/PubMed/Corpus">005812</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005812</idno><idno type="wicri:Area/PubMed/Curation">005812</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005812</idno><idno type="wicri:Area/PubMed/Checkpoint">005812</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005812</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety and efficacy of human growth hormone treatment in girls with Turner syndrome.</title><author><name sortKey="Price, D A" sort="Price, D A" uniqKey="Price D" first="D A" last="Price">D A Price</name><affiliation wicri:level="1"><nlm:affiliation>Department of Child Health, Manchester University, Royal Manchester Children's Hospital, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Child Health, Manchester University, Royal Manchester Children's Hospital</wicri:regionArea><wicri:noRegion>Royal Manchester Children's Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Clayton, P E" sort="Clayton, P E" uniqKey="Clayton P" first="P E" last="Clayton">P E Clayton</name></author><author><name sortKey="Crowne, E H" sort="Crowne, E H" uniqKey="Crowne E" first="E H" last="Crowne">E H Crowne</name></author><author><name sortKey="Roberts, C R" sort="Roberts, C R" uniqKey="Roberts C" first="C R" last="Roberts">C R Roberts</name></author></analytic><series><title level="j">Hormone research</title><idno type="ISSN">0301-0163</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Behavior (drug effects)</term><term>Blood Glucose (analysis)</term><term>Blood Pressure (drug effects)</term><term>Body Height (drug effects)</term><term>Child</term><term>Dose-Response Relationship, Drug</term><term>Encopresis (chemically induced)</term><term>Encopresis (psychology)</term><term>Enuresis (chemically induced)</term><term>Enuresis (psychology)</term><term>Female</term><term>Growth (drug effects)</term><term>Growth Hormone (adverse effects)</term><term>Growth Hormone (therapeutic use)</term><term>Hemoglobin A, Glycosylated (analysis)</term><term>Humans</term><term>Lymphedema (chemically induced)</term><term>Recombinant Proteins (adverse effects)</term><term>Recombinant Proteins (therapeutic use)</term><term>Regression Analysis</term><term>Seizures (chemically induced)</term><term>Tic Disorders (chemically induced)</term><term>Triglycerides (blood)</term><term>Turner Syndrome (drug therapy)</term><term>Turner Syndrome (psychology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Analyse de régression</term><term>Comportement ()</term><term>Crises épileptiques ()</term><term>Croissance ()</term><term>Encoprésie ()</term><term>Encoprésie (psychologie)</term><term>Enfant</term><term>Femelle</term><term>Glycémie (analyse)</term><term>Hormone de croissance (effets indésirables)</term><term>Hormone de croissance (usage thérapeutique)</term><term>Humains</term><term>Hémoglobine A glycosylée (analyse)</term><term>Lymphoedème ()</term><term>Pression sanguine ()</term><term>Protéines recombinantes (effets indésirables)</term><term>Protéines recombinantes (usage thérapeutique)</term><term>Relation dose-effet des médicaments</term><term>Syndrome de Turner (psychologie)</term><term>Syndrome de Turner (traitement médicamenteux)</term><term>Taille ()</term><term>Triglycéride (sang)</term><term>Troubles des tics ()</term><term>Énurésie ()</term><term>Énurésie (psychologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Growth Hormone</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Blood Glucose</term><term>Hemoglobin A, Glycosylated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Triglycerides</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Glycémie</term><term>Hémoglobine A glycosylée</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Encopresis</term><term>Enuresis</term><term>Lymphedema</term><term>Seizures</term><term>Tic Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior</term><term>Blood Pressure</term><term>Body Height</term><term>Growth</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Turner Syndrome</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hormone de croissance</term><term>Protéines recombinantes</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Encoprésie</term><term>Syndrome de Turner</term><term>Énurésie</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Encopresis</term><term>Enuresis</term><term>Turner Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Triglycéride</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Growth Hormone</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome de Turner</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hormone de croissance</term><term>Protéines recombinantes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Child</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Regression Analysis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Analyse de régression</term><term>Comportement</term><term>Crises épileptiques</term><term>Croissance</term><term>Encoprésie</term><term>Enfant</term><term>Femelle</term><term>Humains</term><term>Lymphoedème</term><term>Pression sanguine</term><term>Relation dose-effet des médicaments</term><term>Taille</term><term>Troubles des tics</term><term>Énurésie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Six major adverse medical events (AMEs) and 44 minor AMEs were recorded in 6 and 23 patients, respectively, during human growth hormone (GH) treatment of Turner syndrome, equivalent to 118 treatment years. During the first year of GH treatment, there was no change in the SD score (SDS) for systolic or diastolic blood pressure. In a subgroup of 20 patients, there was no change in psychological tests, oral glucose tolerance, glycosylated haemoglobin or serum triglycerides over the first year of GH treatment. The mean total serum cholesterol level fell over this period. The low incidence of adverse medical problems during GH treatment complemented its efficacy. Height velocity in the first year was 7.7 +/- 1.8 cm/year (mean +/- SD) and was correlated with maternal height SDS, though not with paternal height SDS. Some 36% of first-year height velocity SDS could be predicted by the dose of GH and maternal height SDS.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8359788</PMID><DateCreated><Year>1993</Year><Month>09</Month><Day>30</Day></DateCreated><DateCompleted><Year>1993</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0301-0163</ISSN><JournalIssue CitedMedium="Print"><Volume>39 Suppl 2</Volume><PubDate><Year>1993</Year></PubDate></JournalIssue><Title>Hormone research</Title><ISOAbbreviation>Horm. Res.</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of human growth hormone treatment in girls with Turner syndrome.</ArticleTitle><Pagination><MedlinePgn>44-8</MedlinePgn></Pagination><Abstract><AbstractText>Six major adverse medical events (AMEs) and 44 minor AMEs were recorded in 6 and 23 patients, respectively, during human growth hormone (GH) treatment of Turner syndrome, equivalent to 118 treatment years. During the first year of GH treatment, there was no change in the SD score (SDS) for systolic or diastolic blood pressure. In a subgroup of 20 patients, there was no change in psychological tests, oral glucose tolerance, glycosylated haemoglobin or serum triglycerides over the first year of GH treatment. The mean total serum cholesterol level fell over this period. The low incidence of adverse medical problems during GH treatment complemented its efficacy. Height velocity in the first year was 7.7 +/- 1.8 cm/year (mean +/- SD) and was correlated with maternal height SDS, though not with paternal height SDS. Some 36% of first-year height velocity SDS could be predicted by the dose of GH and maternal height SDS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Price</LastName><ForeName>D A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Child Health, Manchester University, Royal Manchester Children's Hospital, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clayton</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Crowne</LastName><ForeName>E H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>C R</ForeName><Initials>CR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Horm Res</MedlineTA><NlmUniqueID>0366126</NlmUniqueID><ISSNLinking>0301-0163</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Hemoglobin A, Glycosylated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-72-6</RegistryNumber><NameOfSubstance UI="D013006">Growth Hormone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001827" MajorTopicYN="N">Body Height</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004688" MajorTopicYN="N">Encopresis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004775" MajorTopicYN="N">Enuresis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006128" MajorTopicYN="N">Growth</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013006" MajorTopicYN="N">Growth Hormone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Hemoglobin A, Glycosylated</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013981" MajorTopicYN="N">Tic Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014424" MajorTopicYN="N">Turner Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8359788</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><noCountry><name sortKey="Clayton, P E" sort="Clayton, P E" uniqKey="Clayton P" first="P E" last="Clayton">P E Clayton</name><name sortKey="Crowne, E H" sort="Crowne, E H" uniqKey="Crowne E" first="E H" last="Crowne">E H Crowne</name><name sortKey="Roberts, C R" sort="Roberts, C R" uniqKey="Roberts C" first="C R" last="Roberts">C R Roberts</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Price, D A" sort="Price, D A" uniqKey="Price D" first="D A" last="Price">D A Price</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004F72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004F72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:8359788
|texte= Safety and efficacy of human growth hormone treatment in girls with Turner syndrome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:8359788" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |